Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab or Envafolimab plus Endostatin for Lung Cancer Leptomeningeal Metastasis
NCT05385185Phase 2Unknown
- Sponsor
- Hebei Medical University
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label trial of endostar in leptomeningeal metastasis (LM) and lung cancer, sponsored by Hebei Medical University. Primary endpoint: 3-month Overall Survival Rate. Status: unknown.
02
Drugs
endostar
03
Conditions
leptomeningeal metastasis (LM)lung cancer
Beyond the preview
Go deeper on NCT05385185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385185.